The tweet was deleted by the author.
But we saved everything 🙂.
Neumora Therapeutics has presented new data on NMRA-215, an oral NLRP3 inhibitor in the company pipeline for obesity treatment. The compound is noted for its high brain penetration and is currently under development for obesity indications.
The update was provided during the companys poster presentation at ObesityWeek, highlighting the ongoing progress in Neumora Therapeutics drug research for obesity.
View post on X Loading...